Cargando…

Clinical application of expectorant therapy in chronic inflammatory airway diseases (Review)

Airway mucus hypersecretion is a significant clinical and pathological feature of chronic inflammatory airway diseases. Its clinical presentations include recurrent coughing and phlegm. Airway mucus is closely associated with the occurrence, development and prognosis of chronic inflammatory airway d...

Descripción completa

Detalles Bibliográficos
Autores principales: ZHANG, TING, ZHOU, XIANGDONG
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3961124/
https://www.ncbi.nlm.nih.gov/pubmed/24660026
http://dx.doi.org/10.3892/etm.2014.1494
_version_ 1782308233301458944
author ZHANG, TING
ZHOU, XIANGDONG
author_facet ZHANG, TING
ZHOU, XIANGDONG
author_sort ZHANG, TING
collection PubMed
description Airway mucus hypersecretion is a significant clinical and pathological feature of chronic inflammatory airway diseases. Its clinical presentations include recurrent coughing and phlegm. Airway mucus is closely associated with the occurrence, development and prognosis of chronic inflammatory airway diseases and critically affects the lung function, quality of life, hospitalization rate and mortality of patients with chronic inflammatory airway diseases. Therefore, expectorant therapies targeting the potential mechanisms of mucus hypersecretion have been the focus of numerous studies. Conventional expectorants are mainly mucoactive medicines, including nausea-stimulating expectorants, mucolytics, mucokinetics, and proteases and nucleases. In addition, certain traditional Chinese herbal medicines and non-mucoactive agents, including muscarinic acetylcholine receptor antagonists, corticosteroids, leukotriene receptor antagonists and macrolide antibiotics, have also shown expectorant effects. Several novel medicines for expectorant therapy have emerged, including cholesterol-lowering statins, epidermal growth factor receptor tyrosine kinase inhibitors, phosphodiesterase-4 inhibitors, stanozolol, surfactants, flavonoids, tachykinin receptor antagonists, protease inhibitors, cytokine antagonists and purinergic agonists. With the increasing number of multidisciplinary studies, the effectiveness of expectorant therapy for the treatment of chronic inflammatory airway diseases has been confirmed. Therefore, the development of novel expectorants and the standardization of expectorant therapy are the direction and focus of future studies, thus benefiting patients who have a chronic inflammatory airway disease.
format Online
Article
Text
id pubmed-3961124
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-39611242014-03-21 Clinical application of expectorant therapy in chronic inflammatory airway diseases (Review) ZHANG, TING ZHOU, XIANGDONG Exp Ther Med Articles Airway mucus hypersecretion is a significant clinical and pathological feature of chronic inflammatory airway diseases. Its clinical presentations include recurrent coughing and phlegm. Airway mucus is closely associated with the occurrence, development and prognosis of chronic inflammatory airway diseases and critically affects the lung function, quality of life, hospitalization rate and mortality of patients with chronic inflammatory airway diseases. Therefore, expectorant therapies targeting the potential mechanisms of mucus hypersecretion have been the focus of numerous studies. Conventional expectorants are mainly mucoactive medicines, including nausea-stimulating expectorants, mucolytics, mucokinetics, and proteases and nucleases. In addition, certain traditional Chinese herbal medicines and non-mucoactive agents, including muscarinic acetylcholine receptor antagonists, corticosteroids, leukotriene receptor antagonists and macrolide antibiotics, have also shown expectorant effects. Several novel medicines for expectorant therapy have emerged, including cholesterol-lowering statins, epidermal growth factor receptor tyrosine kinase inhibitors, phosphodiesterase-4 inhibitors, stanozolol, surfactants, flavonoids, tachykinin receptor antagonists, protease inhibitors, cytokine antagonists and purinergic agonists. With the increasing number of multidisciplinary studies, the effectiveness of expectorant therapy for the treatment of chronic inflammatory airway diseases has been confirmed. Therefore, the development of novel expectorants and the standardization of expectorant therapy are the direction and focus of future studies, thus benefiting patients who have a chronic inflammatory airway disease. D.A. Spandidos 2014-04 2014-01-21 /pmc/articles/PMC3961124/ /pubmed/24660026 http://dx.doi.org/10.3892/etm.2014.1494 Text en Copyright © 2014, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Articles
ZHANG, TING
ZHOU, XIANGDONG
Clinical application of expectorant therapy in chronic inflammatory airway diseases (Review)
title Clinical application of expectorant therapy in chronic inflammatory airway diseases (Review)
title_full Clinical application of expectorant therapy in chronic inflammatory airway diseases (Review)
title_fullStr Clinical application of expectorant therapy in chronic inflammatory airway diseases (Review)
title_full_unstemmed Clinical application of expectorant therapy in chronic inflammatory airway diseases (Review)
title_short Clinical application of expectorant therapy in chronic inflammatory airway diseases (Review)
title_sort clinical application of expectorant therapy in chronic inflammatory airway diseases (review)
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3961124/
https://www.ncbi.nlm.nih.gov/pubmed/24660026
http://dx.doi.org/10.3892/etm.2014.1494
work_keys_str_mv AT zhangting clinicalapplicationofexpectoranttherapyinchronicinflammatoryairwaydiseasesreview
AT zhouxiangdong clinicalapplicationofexpectoranttherapyinchronicinflammatoryairwaydiseasesreview